Vera Therapeutics Inc.

NASDAQ: VERA · Real-Time Price · USD
25.39
0.08 (0.32%)
At close: May 05, 2025, 3:59 PM
25.53
0.55%
After-hours: May 05, 2025, 05:54 PM EDT
0.32%
Bid 23.5
Market Cap 1.62B
Revenue (ttm) n/a
Net Income (ttm) -152.15M
EPS (ttm) -2.75
PE Ratio (ttm) -9.23
Forward PE -7.52
Analyst Buy
Ask 27
Volume 572,431
Avg. Volume (20D) 1,066,617.5
Open 25.36
Previous Close 25.31
Day's Range 24.62 - 25.84
52-Week Range 18.53 - 51.61
Beta 1.27

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 112
Stock Exchange NASDAQ
Ticker Symbol VERA
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $68, which is an increase of 167.82% from the latest price.

Stock Forecasts
3 months ago
-6.08%
Vera Therapeutics shares are trading lower. The co... Unlock content with Pro Subscription
6 months ago
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.